126 related articles for article (PubMed ID: 38735585)
21. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
Tawfik A
Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
[TBL] [Abstract][Full Text] [Related]
22. Prostate Cancer Foundation Screening Guidelines for Black Men in the United States.
Garraway IP; Carlsson SV; Nyame YA; Vassy JL; Chilov M; Fleming M; Frencher SK; George DJ; Kibel AS; King SA; Kittles R; Mahal BA; Pettaway CA; Rebbeck T; Rose B; Vince R; Winn RA; Yamoah K; Oh WK
NEJM Evid; 2024 May; 3(5):EVIDoa2300289. PubMed ID: 38815168
[TBL] [Abstract][Full Text] [Related]
23. Rural-Urban Differences in Prostate-Specific Antigen (PSA) Screening and Its Outcomes in New Zealand.
Obertová Z; Hodgson F; Scott-Jones J; Brown C; Lawrenson R
J Rural Health; 2016; 32(1):56-62. PubMed ID: 26174590
[TBL] [Abstract][Full Text] [Related]
24. The Relationship Between Education and Prostate-Specific Antigen Testing Among Urban African American Medicare Beneficiaries.
Hararah MK; Pollack CE; Garza MA; Yeh HC; Markakis D; Phelan-Emrick DF; Wenzel J; Shapiro GR; Bone L; Johnson L; Ford JG
J Racial Ethn Health Disparities; 2015 Jun; 2(2):176-83. PubMed ID: 26863336
[TBL] [Abstract][Full Text] [Related]
25. The Impact of Receipt of Information on Prostate-Specific Antigen Testing on Screening with the Prostate-Specific Antigen Test.
McCormick ME; Haile ZT
J Cancer Educ; 2023 Aug; 38(4):1313-1321. PubMed ID: 36652189
[TBL] [Abstract][Full Text] [Related]
26. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
Carlsson S; Assel M; Sjoberg D; Ulmert D; Hugosson J; Lilja H; Vickers A
BMJ; 2014 Mar; 348():g2296. PubMed ID: 24682399
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen testing rates in high-risk populations: results from the All of Us Research Program.
Morley F; Iyer HS; Tamimi RM; Nanus DM; Rebbeck TR; Kensler KH
Cancer Causes Control; 2024 Mar; 35(3):509-521. PubMed ID: 37878135
[TBL] [Abstract][Full Text] [Related]
28. Downstream tests, treatments, and annual direct payments in older men cared for by primary care providers with high or low prostate-specific antigen screening rates using 100 percent Texas U.S. Medicare public insurance claims data: a retrospective cohort study.
Zanwar P; Lin YL; Kuo YF; Goodwin JS
BMC Health Serv Res; 2016 Jan; 16():17. PubMed ID: 26772175
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific antigen screening among young men in the United States.
Scales CD; Antonelli J; Curtis LH; Schulman KA; Moul JW
Cancer; 2008 Sep; 113(6):1315-23. PubMed ID: 18696715
[TBL] [Abstract][Full Text] [Related]
30. Prostate Cancer Screening Uptake in Transgender Women.
Kalavacherla S; Riviere P; Kalavacherla S; Anger JT; Murphy JD; Rose BS
JAMA Netw Open; 2024 Feb; 7(2):e2356088. PubMed ID: 38353948
[TBL] [Abstract][Full Text] [Related]
31. Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial.
Barocas DA; Grubb R; Black A; Penson DF; Fowke JH; Andriole G; Crawford ED
Cancer; 2013 Jun; 119(12):2223-9. PubMed ID: 23559420
[TBL] [Abstract][Full Text] [Related]
32. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
Jemal A; Fedewa SA; Ma J; Siegel R; Lin CC; Brawley O; Ward EM
JAMA; 2015 Nov; 314(19):2054-61. PubMed ID: 26575061
[TBL] [Abstract][Full Text] [Related]
33. Disparities Associated with Shared Decision-making in Prostate Cancer Screening.
Basin MF; Crane K; Basnet A; Chandrasekar T; Shapiro O; Jacob JM; Bratslavsky G; Goldberg H
Eur Urol Focus; 2023 Nov; 9(6):1008-1015. PubMed ID: 37198068
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study.
Young GJ; Harrison S; Turner EL; Walsh EI; Oliver SE; Ben-Shlomo Y; Evans S; Lane JA; Neal DE; Hamdy FC; Donovan JL; Martin RM; Metcalfe C
BMJ Open; 2017 Oct; 7(10):e017729. PubMed ID: 29084797
[TBL] [Abstract][Full Text] [Related]
35. Total, free, and percent free prostate-specific antigen levels among U.S. men, 2001-04.
Lacher DA; Thompson TD; Hughes JP; Saraiya M
Adv Data; 2006 Dec; (379):1-12. PubMed ID: 17348177
[TBL] [Abstract][Full Text] [Related]
36. Five-year downstream outcomes following prostate-specific antigen screening in older men.
Walter LC; Fung KZ; Kirby KA; Shi Y; Espaldon R; O'Brien S; Freedland SJ; Powell AA; Hoffman RM
JAMA Intern Med; 2013 May; 173(10):866-73. PubMed ID: 23588999
[TBL] [Abstract][Full Text] [Related]
37. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
38. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening.
Leapman MS; Wang R; Park H; Yu JB; Sprenkle PC; Cooperberg MR; Gross CP; Ma X
JAMA Oncol; 2022 Jan; 8(1):41-47. PubMed ID: 34762100
[TBL] [Abstract][Full Text] [Related]
39. Prostate-Specific Antigen Testing Initiation and Shared Decision-Making: Findings from the 2000 and 2015 National Health Interview Surveys.
Li J; Ding H; Richards TB; Martin I; Kobrin S; Marcus PM
J Am Board Fam Med; 2018; 31(4):658-662. PubMed ID: 29986994
[TBL] [Abstract][Full Text] [Related]
40. Prostate carcinoma among men with human immunodeficiency virus infection.
Crum NF; Spencer CR; Amling CL
Cancer; 2004 Jul; 101(2):294-9. PubMed ID: 15241826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
